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Purpose: Asymptomatic chronic inflammation of the prostate is a common finding in 
benign prostatic hyperplasia (BPH). We investigated how the chronic inflammation 
affects medical treatment for BPH.
Materials and Methods: One pathologist reviewed the chronic inflammation of 82 BPH 
patients who underwent transrectal ultrasonography (TRUS)-guided needle biopsy. 
The extent of chronic inflammation was classified into 4 grades, categorized into two 
groups: the low-grade group and the high-grade group. We compared total, voiding, and 
storage International Prostate Symptom Score (IPSS) and quality of life (QoL) between 
the groups at baseline and 1, 3, 6, and 12 months after medical treatment for BPH. 
Results: There were no significant differences in total IPSS or QoL between the groups 
during the follow-up period. The low-grade group showed continuous improvement of 
storage symptoms until 12 months; however, the high-grade group showed improve-
ment until 3 months. Maximal improvements of QoL were observed at 6 months in the 
high-grade group and at 3 months in the low-grade group. There was no episode of sur-
gery in the low-grade group, but four patients in the high-grade group (9.1%) underwent 
surgical treatment due to acute urinary retention or insufficient therapeutic response. 
Conclusions: Although there was no statistical significance, improvements in IPSS 
were higher and lasted longer in the low-grade group. We might suggest medical treat-
ment for intraprostatic chronic inflammation in BPH patients.
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is a progressive dis-
ease that causes lower urinary tract symptoms (LUTS), 
causes acute urinary retention (AUR), or leads to BPH-re-
lated surgery, and it greatly affects quality of life (QoL) 
[1,2]. It has also been reported that intraprostatic infla-
mmation frequently accompanies BPH and accelerates the 
pathogenesis and progression of this condition [3-7]. Acute 
intraprostatic inflammation causes symptoms that can be 
easily treated. However, many cases of chronic intrapro-
static inflammation go untreated because the condition 
has no symptoms. 
　We conducted this study to identify the effects of intra-
prostatic inflammation on therapeutic results in patients 
who receive medical treatment for BPH.
MATERIALS AND METHODS
This study retrospectively analyzed the medical records of 
82 patients with abnormal prostate-specific antigen (PSA) 
and digital rectal examination results who were diagnosed 
with prostatic hyperplasia by biopsy and who had received 
drug treatment with alpha-adrenergic blockers (α-block-
ers) and 5-alpha reductase inhibitors between September 
2005 and June 2008. The study analyzed patients who 
could be followed up for six months or longer. Patients with 
urinary tract infection, prostate cancer, urethral stricture, 
or neurogenic bladder and patients who underwent BPH- 
related surgery were excluded from the study. 
　One pathologist reviewed the intraprostatic infla-
mmation of 82 patients. The extent of intraprostatic infla-
mmation was classified on the basis of the four-point scale 
proposed by Irani et al [8]. This scale includes four grades: Korean J Urol 2010;51:266-270
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TABLE 1. Baseline values of the low- and high-grade groups 
before treatment
IPSS
Baseline values of the groups 
before treatment (n)
Low grade 
(38)
High grade 
(44)
p-value
IPSS
  Storage
  Voiding
  Total
QoL
Prostate volume (ml)
PSA (ng/ml)
Age (years)
8.1±0.97
11.8±1.36
19.9±1.98
4.1±0.27
51.0±3.64
7.9±1.14
62.9±8.12
7.3±0.49
10.8±0.96
18.1±1.22
3.6±0.19
64.0±5.47
9.0±1.20
66.0±4.99
0.446
0.539
0.468
0.108
0.073
0.506
0.125
Low grade: chronic inflammation grade 0, I, High grade: chronic 
inflammation grade II, III, IPSS: international prostate symptom 
score, QoL: quality of life, PSA: prostate-specific antigen
TABLE 2. Mean changes from baseline in the low- and high-grade groups after treatment
Mean changes over baseline of the groups after treatment (n)
1 month (82) 3 months (82) 6 months (82) 12 months (78)
a
Low vs. High Low vs. High Low vs. High Low vs. High
IPSS Storage
Voiding
Total
QoL
−2.5
c vs. −2.2
b,c
−4.2
c vs. −2.8
b,c
−6.7
c vs. −5.0
b,c
−0.6
c vs. −0.3
b,c
−3.2
c vs. −2.4
b,c
−5.0
c vs. −4.3
b,c
−8.2
c,d vs. −6.7
b,c
−1.1
c vs. −0.6
b,c
−3.9
c vs. −2.3
b,c
−6.3
c,d vs. −4.4
b,c
−10.2
c,d vs. −6.7
b,c
−1.0
c vs. −0.9
b,c
−4.0
c vs. −2.1
b,c
−5.7
c vs. −4.2
b,c
−9.7
c vs. −6.3
b,c
−0.8
c vs. −0.7
b,c
Low: low grade group (chronic inflammation grade O, I), High: high grade group (chronic inflammation grade II, III), IPSS: international 
prostate symptom score, QoL: quality of life, PSA: prostate-specific antigen, 
a: 4 cases received transurethral resection of the prostate, 
b: p-value (＞0.05) of between low & high grade groups (independent t-test), 
c: p＜0.05 vs. baseline; statistical significance within groups 
(paired t-test), 
d: p＜0.05 vs. previous IPSS (except baseline); statistical significance within groups (ANOVA test)
FIG. 1. Mean changes in total IPSS during 12 months. IPSS: Inter-
national Prostate Symptom Score, High-grade group: chronic in-
flammation grades II and III, Low-grade group: chronic infla-
mmation grades 0 and I. The improvement of IPSS in the low- 
grade group was higher and longer for 12 months.
grade 0 (no inflammatory cells), grade I (scattered infla-
mmatory cell infiltrate within the stroma without lym-
phoid nodules), grade II (nonconfluent lymphoid nodules), 
and grade III (large inflammatory areas with confluence 
of infiltrate). 
　The subjects were then divided into the low-grade group 
(grades 0 and I), which consisted of 38 cases (46%), and the 
high-grade group (grades II and III) of 44 cases (54%). The 
International Prostate Symptom Score (IPSS) and QoL of 
the groups before treatment and at 1, 3, 6, and 12 months 
of treatment, as well whether they had undergone surgery, 
were compared so as to identify the effects of intraprostatic 
inflammation on the medical treatment of BPH. Statistical 
analysis was performed by using Student’s t-test and 
ANOVA test of SPSS, version 12.0. p-values＜0.05 were 
considered statistically significant.
RESULTS
A total of 6, 32, 35, and 9 patients had grade 0, I, II, and 
III inflammation. The prostate volume of 38 cases in the 
low-grade group (46%) and 44 cases in the high-grade group 
(54%) before treatment were 51.0±3.64 ml and 64.0±5.47 
ml (p=0.073), respectively; PSA values were 7.9±1.14 
ng/ml and 9.0±1.20 ng/ml (p=0.506), respectively; IPSS 
were 19.9± 1.98 and 18.1±1.22 (p=0.468), respectively; and 
QoL scores were 4.1±0.27 and 3.6±0.19 (p=0.108), re-
spectively (Table 1).
　The improvements of IPSS at 1, 3, 6, and 12 months of 
treatment were −6.7±2.02, −8.2±2.14, −10.2±1.92, and 
−9.7±1.70, respectively in the low-grade group, and −5.0± 
1.24, −6.7±1.45, −6.7±1.65, and −6.3±1.57, respectively, 
in the high-grade group. All the improvements compared 
with IPSS before treatment were statistically significant, 
but there was no significant difference in improvement be-
tween the two groups (p=0.463, p=0.558, p=0.174, and p= 
0.146, respectively). Compared with previous total IPSS, 
there were significant improvements in the low-grade 
group until 6 months (1 month vs. 3 month, 3 months vs. 
6 months: p=0.04, p=0.04) (Table 2). Both groups showed 
the highest improvements at 6 months of drug treatment, 
but the improvement in the low-grade group was 3.5 points 
higher than that of the high-grade group, which was the Korean J Urol 2010;51:266-270
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FIG. 2. Mean changes in storage symptom score during 12 months. 
High-grade group: chronic inflammation grades II and III, Low- 
grade group: chronic inflammation grades 0 and I. The low-grade 
group showed continuous improvement of storage symptoms 
until 12 months; however, the high-grade group showed improve-
ment until 3 months.
FIG. 3. Mean changes in QoL score during 12 months. QoL: 
quality of life, High-grade group: chronic inflammation grades II 
and III, Low-grade group: chronic inflammation grades 0 and I. 
Maximal improvements of QoL were observed at 6 months in the 
high-grade group and at 3 months in the low-grade group.
greatest difference during the treatment period (Fig. 1). 
The changes in storage symptoms at 1, 3, 6, and 12 months 
of treatment were −2.5±0.96, −3.2±0.95, −3.9±0.92, and 
−4.0±0.92, respectively, in the low-grade group, and −
2.2±0.53, −2.4±0.53, −2.3±0.60, and −2.1±0.55, respec-
tively, in the high-grade group. The low-grade group show-
ed continuous improvement until 12 months of drug treat-
ment, whereas the improvement of the high-grade group 
tended to decrease after 3 months (Fig. 2).
　The improvement in QoL relative to before treatment 
was significant in both groups. The low-grade group show-
ed improvements of −0.6±0.28, −1.1±0.30, −1.0±0.31, 
and −0.8±0.31 at 1, 3, 6, and 12 months of treatment, re-
spectively, and the high-grade group showed improve-
ments of −0.3±0.17, −0.6±0.26, −0.9±0.26, and −0.7± 
0.27, respectively. There was no significant difference be-
tween the two groups (p=0.362, p=0.309, p=0.846, and p= 
0.701, respectively). However, it took 3 months of treat-
ment before the low-grade group showed its highest im-
provement in QoL and 6 months for the high-grade group 
(Table 2, Fig. 3). Four cases from the high-grade group un-
derwent prostate surgery after six months of drug treat-
ment.
DISCUSSION
Kohnen et al reported that when prostate tissue is removed 
by surgery from prostatic hyperplasia patients with no 
symptoms of acute prostatitis, asymptomatic intrapro-
static chronic inflammation National Institute of Health 
(NIH) category IV is observed in 43% to 98% of cases [9]. 
Nickel et al reported on the basis of the REduction by 
DUtasteride of prostate Cancer Events (REDUCE) study 
that chronic inflammation is observed in 77.6% of patients 
with lower urinary tract symptoms and that the higher the 
average chronic inflammation score, the higher the IPSS 
[10]. In their studies on the correlation between intrapro-
static chronic inflammation and BPH, Roehrborn et al and 
Nickel et al claimed that intraprostatic chronic inflamma-
tion affects the progression of prostatic hyperplasia [3,11]. 
Mishra et al also insisted that asymptomatic intraprostatic 
chronic inflammation can affect BPH progression and acu-
te urinary retention [4-6]. However, there are still no clini-
cal studies of the correlation between intraprostatic in-
flammation and the therapeutic effects of prostatic hyper-
plasia. Thus, a study on this subject is warranted. 
　The present study divided prostatic hyperplasia pa-
tients into a low-grade group and a high-grade group on the 
basis of the four-point scale for the extent of intraprostatic 
inflammation as proposed by Irani et al [8]. We investi-
gated the clinical effects of intraprostatic inflammation on 
the drug treatment of BPH patients by analyzing the im-
provements in IPSS and QoL as recorded by the patients 
themselves at 1, 3, 6, and 12 months of drug treatment. The 
improvements in IPSS and QoL after drug treatment 
showed no statistical differences between the two groups, 
but the improvements of the low-grade group were more 
continuous and greater than those of the high-grade group 
during the follow-up period. In particular, compared with 
previous total IPSS, there were significant improvements 
in the low-grade group until 6 months (1 month vs. 3 
months, 3 months vs. 6 months: p=0.04, p=0.04), and the 
improvement in storage symptoms continued for 12 mon-
ths. Furthermore, it took 3 months until the highest im-
provement of QoL in the low-grade group was seen, and 6 
months in the high-grade group. This shows that the re-
action of the low-grade group to drug treatment for pro-
static hyperplasia was faster than that of the high-grade 
group (Fig. 3). 
　Although Nickel et al reported that the higher the aver-
age chronic inflammation score, the higher the IPSS, this 
study did not find any difference in IPSS or QoL before Korean J Urol 2010;51:266-270
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treatment between the two groups [10]. The reason for this 
appears to be that this study performed transrectal ultra-
sonography-guided needle biopsy (TRUSBx) for patients 
with high PSA and excluded subjects who had acute uri-
nary retention and those who had undergone BPH-related 
surgery. 
　Kang et al compared the effects of drug treatment be-
tween two groups who were divided by the existence of pros-
tatitis through prostate massage [12]. They found that 
those with prostatitis experienced less improvement in 
storage symptoms from the drug treatment of prostatic hy-
perplasia than did those with no prostatitis. This was sim-
ilar to the result of the present study, which divided sub-
jects into two groups according to the extent of intrapro-
static inflammation through TRUSBx. 
　Roehrborn et al and Ha et al reported that more severe 
intraprostatic inflammation has a greater impact on BPH 
progression and acute urinary retention [3,7]. Kefi et al also 
stated that intraprostatic chronic inflammation is a more 
meaningful factor affecting acute urinary retention than 
prostate volume, PSA, and age [5]. During the follow-up in 
our study, one patient underwent transurethral resection 
of the prostate due to the development of acute urinary re-
tention and three patients underwent the same surgery 
due to the lack of efficacy of the medication. The intrapro-
static inflammation in these patients was all high grade. 
The mean prostate volume of the patients whose drug treat-
ment had failed was 58.75 ml, the mean IPSS was 19 points, 
the mean PSA was 4.04 ng/ml, the mean QoL was 3.75, and 
the mean age was 70.75. Statistical comparison with other 
patients was not reasonable because of the low number of 
cases. However, because all the patients who received sur-
gery were in the high-grade group, we could assume that 
the more severe the inflammation, the higher the possibility 
of the failure of medical treatment. Even though it is not 
possible to perform TRUSBx for all patients before drug 
treatment to find intraprostatic inflammation, we could in-
directly infer inflammation by using inflammatory cyto-
kines such as interleukin-6 and interleukin-8, which are 
involved in intraprostatic inflammation [13-15], or C-re-
active protein, which is a nonspecific inflammation factor.
　Nickel et al examined the tissues of patients who had un-
dergone transurethral resection of the prostate due to BPH 
and found the existence of inflammation in all of them but 
could not find any clinical significance of the asymptomatic 
category IV chronic prostatitis in BPH as a result of the lack 
of meaningful correlation between the degree and pattern 
of inflammation, catheterization, the presence of bacteria, 
and serum PSA or PSA density [16]. However, Collins et 
al claimed that prostatitis could be a risk factor in the devel-
opment of pathological prostatic hyperplasia into clinical 
prostatic hyperplasia [17] and that chronic intraprostatic 
inflammation affects the progress of prostatic hyperplasia 
[10].
　Meanwhile, Nickel presented the importance of addi-
tional treatment of chronic intraprostatic inflammation by 
stating that if the symptoms of prostatic hyperplasia were 
correlated with intraprostatic inflammation, anti-infla-
mmatory agents would be a new treatment goal for pro-
static hyperplasia [18]. It has been reported that IPSS im-
provements as a result of drug treatment of prostatic hy-
perplasia were more significant with the combined therapy 
using an α-blocker and anti-inflammatory agent than with 
the single therapy using an α-blocker alone [19,20]. Minnery 
and Getzenberg also reported that the additional use of ibu-
profen together with an α-blocker for prostatic hyperplasia 
patients was more effective in reducing the expression of 
the JM-27 genes that generate proteins related to prostatic 
hyperplasia and in improving the symptoms of prostatic 
hyperplasia [21]. Many similar studies have found that the 
management of intraprostatic inflammation plays an im-
portant role in the improvement of IPSS in the medical 
treatment of prostatic hyperplasia patients, but studies on 
intraprostatic inflammation and response to drug treat-
ment are still insufficient due to the lack of confirmation 
of inflammation before treatment. 
　This study examined the extent of inflammation through 
TRUSBx and the changes in IPSS and QoL after drug treat-
ment. This study is meaningful because it identified that 
the lower the inflammation, the better the response to drug 
treatment, although there was no statistical significance. 
We believe that additional treatment of inflammation will 
be required in drug treatment of BPH in the future, and a 
large-scale study is necessary to investigate the extent of 
intraprostatic inflammation and the response to medical 
treatment of BPH in a larger number of patients. 
CONCLUSIONS
Ninety-three percent of BPH patients had chronic infla-
mmation. The differences in IPSS and QoL before and after 
drug treatment between the two groups divided by the ex-
tent of intraprostatic inflammation were not statistically 
significant. However, the low-grade group experienced 
greater improvement in IPSS during the treatment period 
and their storage symptoms improved continuously until 
12 months. Furthermore, no patient in the low-grade group 
underwent BPH-related surgery due to failure of medical 
treatment for BPH, but four cases in the high-grade group 
(9.1%) required the surgery. Therefore, we might consider 
whether more active treatment of intraprostatic infla-
mmation is necessary in the medical treatment of BPH. In 
the future, clinical studies on the correlation between in-
traprostatic inflammation and BPH treatment are re-
quired, and such studies should include more cases and a 
longer follow-up period.
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